Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Takehiro Ura"'
Autor:
Takehiro Ura, Masaki Takeuchi, Tatsukata Kawagoe, Nobuhisa Mizuki, Kenji Okuda, Masaru Shimada
Publikováno v:
Vaccines, Vol 10, Iss 8, p 1367 (2022)
The induction of T cell-mediated immunity is crucial in vaccine development. The most effective vaccine is likely to employ both cellular and humoral immune responses. The efficacy of a vaccine depends on T cells activated by antigen-presenting cells
Externí odkaz:
https://doaj.org/article/a416eb688caa4d5d8f09f3a6c0d83aed
Publikováno v:
Vaccines, Vol 2, Iss 3, Pp 624-641 (2014)
Viral vectors are promising tools for gene therapy and vaccines. Viral vector-based vaccines can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells. During the last s
Externí odkaz:
https://doaj.org/article/914cc6cedbd047159fc78aadb00323c7
Publikováno v:
PLoS ONE, Vol 11, Iss 12, p e0167952 (2016)
Skin is protected by a tough but flexible multilayered barrier and is a front line for immune responses against invading particles. For many years now, skin has been a tissue where certain vaccines are injected for the prevention of infectious diseas
Externí odkaz:
https://doaj.org/article/e78178337cae46a58417de2881343b45
Publikováno v:
Gene Therapy. 29:636-642
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d47a173a9c93e1dd7db4f6cec201879e
https://doi.org/10.1038/s41434-021-00308-z
https://doi.org/10.1038/s41434-021-00308-z
Autor:
Michiko Fukuta, Masaru Shimada, Kenji Okuda, Jutaro Nakamura, Nobuhisa Mizuki, Jun Fukushima, Takeshi Teshigawara, Takehiro Ura, Saori Ito
Publikováno v:
Vaccine. 39(23):3152-3160
Pseudomonas aeruginosa (P. aeruginosa) infection is one of the major causes of keratitis. However, effective prophylactic and therapeutic vaccines against P. aeruginosa keratitis have yet to be developed. In this study, we explored the use of P. aeru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::242f294cf67d6184a30150a250327537
http://id.nii.ac.jp/1246/00002248/
http://id.nii.ac.jp/1246/00002248/
Autor:
Masaru, Shimada, Haibin, Wang, Motohide, Ichino, Takehiro, Ura, Nobuhisa, Mizuki, Kenji, Okuda
Publikováno v:
Gene therapy. 29(10-11)
Previously, we developed a chimeric adenovirus type 5 with type 35 fiber (Ad5/35), which has high tropism to dendritic cells and low hepatoxicity. For further clinical use, we constructed two recombinant vectors expressing human immunodeficiency viru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a000345a05928578e1361a6b72ee9cc8
https://pubmed.ncbi.nlm.nih.gov/34987192
https://pubmed.ncbi.nlm.nih.gov/34987192
Publikováno v:
Vaccine
The threat of the current coronavirus disease pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is accelerating the development of potential vaccines. Candidate vaccines have been generated using existing technologies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b299c021fab3d551f159f4646a0d8ef3
https://pubmed.ncbi.nlm.nih.gov/33279318
https://pubmed.ncbi.nlm.nih.gov/33279318
Publikováno v:
Vaccines, Vol 2, Iss 3, Pp 624-641 (2014)
Vaccines
Vaccines
Viral vectors are promising tools for gene therapy and vaccines. Viral vector-based vaccines can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells. During the last s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d317fb3d7963a7602c7c5ce03ecc9409
https://doi.org/10.3390/vaccines2030624
https://doi.org/10.3390/vaccines2030624
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 12, p e0167952 (2016)
PLoS ONE, Vol 11, Iss 12, p e0167952 (2016)
Skin is protected by a tough but flexible multilayered barrier and is a front line for immune responses against invading particles. For many years now, skin has been a tissue where certain vaccines are injected for the prevention of infectious diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf5e77001163c59ba3efbbbb0de299e2
http://europepmc.org/articles/PMC5156430
http://europepmc.org/articles/PMC5156430
Autor:
Kenji Okuda, Takehiro Ura, Shinji Yoshizaki, Shinya Abe, Atsushi Yoshida, Masaru Shimada, Asami Kondo, Dennis M. Klinman, Hiroyuki Mizuguchi
Publikováno v:
J Gene Med
Background Adenovirus type 5 (Ad5) is widely used as a vehicle for vaccine delivery in the treatment of infectious disease and cancer. However, the efficacy of Ad5 vectors has been limited in humans because exposure to Ad5 infections results in most
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d464b14ad7c4dfb33afb61cacd754f71
https://doi.org/10.1002/jgm.1332
https://doi.org/10.1002/jgm.1332